Find a Clinical Trial

A Modified Ketogenic, Anti‐Inflammatory Diet for Patients with High‐Grade Gliomas

A Modified Ketogenic, Anti-Inflammatory Diet for Patients with High-Grade Gliomas

18+

Learn more

The ImmuneSense Study

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma – The ImmuneSense Study

18-70

Learn more

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

18+

Learn more

Non-Interventional Fresh Tumor Tissue

Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue

18+

Learn more

Breast Cancer Database

Breast Cancer Database

18+

Learn more

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/​or Metastatic Breast Cancer

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

16+

Learn more

HER2 Negative Breast Cancer

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

18+

Learn more

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

18+

Learn more

NRG-BN009

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year

18+

Learn more